Stem cell-based therapy to treat liver diseases is a focus of current research.Cell types and the transplantation pathways are the key factors
So far, most such studies used rodent models to evalsuate the therapeutic potential of bone marrow derived mesenchymal stem cells (BMSC) for treating hepatic failure via peripheral vein transplantation.
Li Lanjuan's group established a method for isolating mesenchymal stem cells from human placenta (hPMSCs).An acute liver failure (ALF) model of Chinese miniature pigs was used to explore their therapeutic potential for treating liver disease in large animal model. Reviewer of this paper, Maurizio Parol, said, “This is possibly the first study investigating the therapeutic potential of hPMSCs in a large animal model of ALF”.
Findings:
1、Placenta as a clinical waste can provide an inexhaustible and low cost source of stem cells. Because of their low immunogenicity, high proliferation rate and multiple differentiation potential, hPMSCs could be used as an excellent source of seed cells for the repair of liver damage
2、Portal vein transplantation under B-ultrasonography guidance is much more safe and effective than the jugular vein pathway
This paper was published in BMC Medicine; the first author is Cao Hong Cui.
Over recent decades, A. baumannii has emerged as a major global hospital-acquired pathogen. Bloodstream infections (BSIs) caused by this bacterium carry a mortality rate of up to 60% and imp...
SAHZU Neurologist Prof. LOU Min and her team recently found that, despite an increased risk of symptomatic intracranial hemorrhage, intravenous alteplase provided functional benefit to acute ischemic ...
The genome, made up of DNA, contains not only protein-coding sequences but also a vast array of non-coding regulatory sequences. These two types of sequence work in concert to shape the complex phenot...
